Ascendis Pharma ASMEX:ASNDN 37 ROE % is 1,557.28% as of Mar. 2026. GuruFocus rates MEX:ASNDN with a GF Score™ of 37/100. The stock has 1 warning sign investors should review. Among 1,256 Biotechnology companies, Ascendis Pharma AS ranks better than 99.92% on this metric.
The historical rank and industry rank for Ascendis Pharma AS's ROE % or its related term are showing as below:
MEX:ASNDN'
s ROE % Range Over the Past 10 Years
Min: -874.41 Med: -57.67 Max: -42.94
Current: Negative Equity
During the past 13 years, Ascendis Pharma AS's highest ROE % was -42.94%. The lowest was -874.41%. And the median was -57.67%.
MEX:ASNDN's ROE % is ranked better than 99.92% of 1256
companies
in the Biotechnology industry
Industry Median: -38.26
vs MEX:ASNDN: Negative Equity
Ascendis Pharma AS (MEX:ASNDN) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Ascendis Pharma AS ROE % Related Terms
Ascendis Pharma AS ROE % Historical Data
* Premium members only.
The historical data trend for Ascendis Pharma AS's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ascendis Pharma AS's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascendis Pharma AS ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's ROE % distribution charts can be found below:
* The bar in red indicates where Ascendis Pharma AS's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Ascendis Pharma AS (MEX:ASNDN) has a ROE % of 1,557.28% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Ascendis Pharma AS and its competitors. According to the industry distribution chart, Ascendis Pharma AS ranks #1 out of 1256 companies in the Biotechnology industry, placing it in the top 0.099999999999994%.
Is Ascendis Pharma AS's ROE % too high?
Ascendis Pharma AS's current ROE % is 1,557.28%. Based on the distribution chart, Ascendis Pharma AS ranks #1 out of 1256 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's ROE % compare to SMMT and BBIO?
According to the Biotechnology industry distribution chart, Ascendis Pharma AS ranks #1 out of 1256 companies for ROE %. This places Ascendis Pharma AS in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Ascendis Pharma AS and its competitors. Ascendis Pharma AS's current ROE % is 1,557.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (MEX:ASNDN) has a current ROE % of 1,557.28%. The current ROE % is 1,557.28%. Ascendis Pharma AS's overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Ascendis Pharma AS (MEX:ASNDN), the current ROE % is 1,557.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score
Get the complete analysis for MEX:ASNDN
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ASNDN has been successfully added to your 
